Literature DB >> 17395341

Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.

Robert P Webb1, Theresa J Smith, Patrick M Wright, Vicki A Montgomery, Michael M Meagher, Leonard A Smith.   

Abstract

Recombinant botulinum Hc (rBoNT Hc) vaccines for serotypes C1 and D were produced in the yeast Pichia pastoris and used to determine protection against four distinct BoNT C and D toxin subtypes. Mice were vaccinated with rBoNT/C1 Hc, rBoNT/D Hc, or with a combination of both vaccines and challenged with BoNT C1, D, C/D, or D/C toxin. Mice receiving monovalent vaccinations were partially or completely protected against homologous toxin and not protected against heterologous toxin. Bivalent vaccine candidates completely survived challenges from all toxins except D/C toxin. These results indicate the recombinant C1 and D Hc vaccines are not only effective in a monovalent formula but offer complete protection against both parental and C/D mosaic toxin and partial protection against D/C mosaic toxin when delivered as a bivalent vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17395341     DOI: 10.1016/j.vaccine.2007.02.081

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

Review 2.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

4.  In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.

Authors:  Easwaran Ravichandran; Pavithra Janardhanan; Kruti Patel; Stephen Riding; Shuowei Cai; Bal Ram Singh
Journal:  Pharm Res       Date:  2015-11-03       Impact factor: 4.200

5.  Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Junwei Li; Diana Diaz-Arévalo; Amit Kumar; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

6.  Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.

Authors:  R Zichel; A Mimran; A Keren; A Barnea; I Steinberger-Levy; D Marcus; A Turgeman; S Reuveny
Journal:  Clin Vaccine Immunol       Date:  2010-03-31

7.  Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.

Authors:  Andrew P-A Karalewitz; Zhuji Fu; Michael R Baldwin; Jung-Ja P Kim; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

8.  Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.

Authors:  Kathryn L Jenko; Yanfeng Zhang; Yulia Kostenko; Yongfeng Fan; Consuelo Garcia-Rodriguez; Jianlong Lou; James D Marks; Susan M Varnum
Journal:  Analyst       Date:  2014-08-12       Impact factor: 4.616

9.  Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Md Elias; Michael E Pichichero; Lance L Simpson; Leonard A Smith
Journal:  Vaccine       Date:  2007-09-05       Impact factor: 3.641

10.  Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.

Authors:  Jerry O Conway; Laura J Sherwood; M Thelma Collazo; John A Garza; Andrew Hayhurst
Journal:  PLoS One       Date:  2010-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.